Technical Analysis for KROS - Keros Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical KROS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| 50 DMA Support | Bullish | -10.70% | |
| Upper Bollinger Band Walk | Strength | -10.70% | |
| Inside Day | Range Contraction | -10.70% | |
| Upper Bollinger Band Touch | Strength | -10.70% | |
| 50 DMA Support | Bullish | -7.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 10% | 1 day ago |
| Down 1 ATR | 1 day ago |
| Down 5% | 1 day ago |
| Fell Below 20 DMA | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get a Trading Sidekick!
- Earnings date: ???
Keros Therapeutics, Inc. Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Hypertension Disorders Hematology Therapeutic Product Pulmonary Arterial Hypertension Anemia Myelodysplastic Syndrome Syndromes Osteoporosis Genodermatoses Myelodysplastic Syndromes Skeletal Disorders Thrombocytopenia Molecule Product Myelofibrosis Bone Disease Blood Disorders Hematopathology Musculoskeletal Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 88.8 |
| 52 Week Low | 25.6 |
| Average Volume | 124,555 |
| 200-Day Moving Average | 55.51 |
| 50-Day Moving Average | 61.34 |
| 20-Day Moving Average | 59.13 |
| 10-Day Moving Average | 60.76 |
| Average True Range | 4.96 |
| ADX | 16.37 |
| +DI | 19.83 |
| -DI | 18.90 |
| Chandelier Exit (Long, 3 ATRs ) | 52.54 |
| Chandelier Exit (Short, 3 ATRs ) | 67.37 |
| Upper Bollinger Band | 64.55 |
| Lower Bollinger Band | 53.71 |
| Percent B (%b) | 0.27 |
| BandWidth | 18.34 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.23 |
| MACD Histogram | 0.2314 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 70.08 | ||||
| Resistance 3 (R3) | 71.20 | 67.85 | 67.84 | ||
| Resistance 2 (R2) | 67.85 | 64.43 | 67.29 | 67.10 | |
| Resistance 1 (R1) | 62.26 | 62.32 | 60.58 | 61.14 | 66.35 |
| Pivot Point | 58.91 | 58.91 | 58.07 | 58.35 | 58.91 |
| Support 1 (S1) | 53.32 | 55.49 | 51.65 | 52.20 | 46.99 |
| Support 2 (S2) | 49.97 | 53.39 | 49.41 | 46.24 | |
| Support 3 (S3) | 44.38 | 49.97 | 45.50 | ||
| Support 4 (S4) | 43.26 |
